Alvin Shih, Retrophin’s (NASDAQ: RTRX) executive vice president and head of R&D, will leave the San Diego-based company at the end of the month. Shih has taken an offer to be the CEO of an unidentified biotech startup.
Sponsored · Whitepaper
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems
Sponsored · Whitepaper
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson
Sponsored · Whitepaper
What the most successful life sciences fundraising pitch decks all have in common
Brex
